Design, Make, Test, Select
Connecting Discovery and Development
Our Design–Make–Test–Select (DMTS) model is a connected workflow that bridges discovery and development to help you reduce cycle times, de-risk candidate selection, and move you quickly toward IND readiness.
- Overview
- Our Design-Make-Test-Select workflow
- Integrated modalities
- What you achieve with DMTS
- What this stage enables for your programme
- In our own words
- FAQs
High attrition, fragmented workflows, and disconnected data remain major barriers in early drug discovery. Many promising candidates fail because traditional outsourcing models lack integration between chemistry, biology, and CMC development.
Our integrated discovery model unites these disciplines under one framework that we call: Design-Make-Test-Select (DMTS).
Our DMTS workflows use real-time collaboration and continuous feedback to reduce design-make-test-analyse cycle times by up to 40% while delivering stronger, more developable drug candidates.
What You Achieve with DMTS
Frequently Asked Questions
Integrated drug discovery services combine chemistry, bioscience, and data analytics within a single connected workflow. At CatSci, our Design–Make–Test–Select (DMTS) platform unites design, synthesis, testing, and selection to generate decision-ready data faster. This integrated approach reduces attrition, accelerates discovery timelines, and ensures every candidate is developed with CMC and regulatory foresight.
Our DMTS platform connects design, make, test, and select stages under one collaborative framework. By aligning chemistry, analytical science, and bioscience in real time, we eliminate data silos and shorten iteration cycles by up to 40% through efficient collaboration, which enables smarter candidate prioritisation. The result is faster progression from concept to IND-ready candidates.
Our integrated drug discovery services support multiple therapeutic modalities, including peptides, oligonucleotides, PROTACs, molecular glues, and hybrid bRo5 constructs. The DMTS model adapts to each modality’s complexity, providing connected design, synthesis, purification, and biological testing workflows that accelerate translation and de-risk development across these diverse drug types.